Jonven Attia, MD
Endocrinology, Diabetes & Metabolism · Seguin, TXNPI 1780067272
Payments from drug & device makers
Across 76 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$240
- Dexcom, Inc.$209
- Medtronic$196
- Novo Nordisk$154
- Tandem Diabetes Care, Inc.$140
- BETA Bionics, Inc.$119
- plus $895 from 21 others
What the payments were for
- Food & beverage$1,92098%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 6 | $240 |
| Dexcom, Inc. | 5 | $209 |
| Medtronic | 7 | $196 |
| Novo Nordisk | 6 | $154 |
| Tandem Diabetes Care, Inc. | 6 | $140 |
| BETA Bionics, Inc. | 6 | $119 |
| Recordati_rare_diseases_inc. | 2 | $114 |
| Lilly USA, LLC | 4 | $81 |
| Ascendis Pharma Endocrinology Inc | 3 | $66 |
| IBSA Pharma Inc. | 3 | $66 |
| AstraZeneca(2 entities) | 3 | $62 |
| Abbott | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Boehringer Ingelheim | 2 | $44 |
| Boston Scientific | 2 | $41 |
| Madrigal Pharmaceuticals | 2 | $41 |
| Antares Pharma, Inc. | 1 | $39 |
| Zealand Pharma US, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Novartis | 1 | $26 |
| AbbVie | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| Bayer | 1 | $17 |
| Cequr Corporation | 1 | $15 |
| Bigfoot Biomedical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$149
- DEXCOM G6 TRANSMITTER$122
- ISTURISA$100
How this compares
$1,952 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 511 | $540,922 |
| MounjaroTirzepatide | 263 | $298,095 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 281 | $196,395 |
| TrulicityDulaglutide | 153 | $184,177 |
| Tresiba Flextouch U-100Insulin Degludec | 336 | $167,828 |
| Xigduo XrDapaglifloz Propaned/Metformin | 240 | $158,865 |
| JardianceEmpagliflozin | 147 | $142,180 |
| FarxigaDapagliflozin Propanediol | 181 | $133,829 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $98,349 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $39,345 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $29,202 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $28,593 |
| RybelsusSemaglutide | 19 | $26,205 |
| Novolog FlexpenInsulin Aspart | 132 | $23,484 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $21,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $154 | $567,127530 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $81 | $487,330446 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $44 | $338,575428 claims |
| AstraZenecaFarxiga | $62 | $133,829181 claims |
| Antares Pharma, Inc.Xyosted | $39 | $7,49413 claims |
| AbbVieSynthroid | $24 | $2,66139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Seguin
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.